Kadmon Pharmaceuticals LLC
Kadmon, a Sanofi Company, is a biopharmaceutical company that discovers, develops and markets transformative therapies for unmet medical needs. Our team has a proven track record of successful drug development and commercialization. Our clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.
REZUROCK™ (belumosudil) tablets is now approved. Please go to rezurockhcp.com to find out more information.
Kadmon is a late clinical-stage clinical biopharmaceutical company discovering and developing transformative therapies for unmet medical needs. Kadmon’s lead product candidate, belumosudil, is an orally administered selective inhibitor of ROCK 2 in development for the treatment of cGVHD and other immune diseases. In September of 2020, Kadmon submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) with belumosudil for the treatment of patients with cGVHD.